Condition
Malignant Neoplasms of Male Genital Organs
Total Trials
7
Recruiting
0
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 7 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
29%
2 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
7Total
P 1 (4)
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Withdrawn3
Completed2
Active Not Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT03435952Phase 1Active Not Recruiting
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
NCT03162627Phase 1Active Not Recruiting
Selumetinib and Olaparib in Solid Tumors
NCT03035357Phase 2WithdrawnPrimary
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
NCT02740127Phase 3CompletedPrimary
Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis
NCT03210376Phase 4Completed
Neuromuscular Blockade on Shoulder Pain of Elderly
NCT02915172Phase 1Withdrawn
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
NCT02812056Phase 1Withdrawn
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
Showing all 7 trials